Is Vepotolizumab/Urova a targeted drug?

Polatuzumab/Polatuzumab is a typical targeted drug and belongs to the category of antibody drug conjugates (ADC). Its targeting property comes from the high affinity recognition ability of the monoclonal antibody part to the specific antigen CD79b on the surface of B cells. CD79b is highly expressed on the surface of B cells and most B-cell lymphoma cells, but its expression is limited in normal tissues, which provides the drug with the ability to accurately attack tumors. Cytotoxins conjugated to drugs and antibodies exert a killing effect after entering cancer cells, achieving "precise killing" and significantly reducing damage to normal cells.

The targeting mechanism makes vepotuzumab uniquely valuable in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL; non-Hodgkin lymphoma). Traditional chemotherapy drugs usually kill tumor cells by non-selectively inhibiting cell division, and can easily cause damage to normal tissues such as bone marrow and digestive tract, leading to significant side effects. Vepotolizumab recognizes tumor cells through antibodies, which can not only concentrate its effect on cancer cells, but also reduce damage to healthy tissues and improve the safety of treatment.

In addition, vepotuzumab is often used in combination chemotherapy regimens to further enhance the anti-tumor effect. Its precise targeting properties can synergize with other drugs, such as the chemotherapy drugs in theR-CHP regimen, which not only exerts the precise killing of targeted drugs, but also ensures the broad-spectrum efficacy of chemotherapy, thereby improving efficacy and disease remission rate. At the same time, its side effects are controllable and patients have a higher quality of life, which is also an important advantage of targeted drugs.

Overseas clinical practice shows that vepotuzumab can still exert good efficacy in patients who have failed multiple lines of treatment, and its targeting characteristics make the tolerance better than traditional chemotherapy drugs. After being launched in China, with the accumulation of clinical experience, doctors can formulate personalized treatment plans based on the patient's specific condition to achieve a balance between maximum efficacy and minimum side effects.

Reference materials:https://www.drugs.com/polivy.html